EXELIXIS, INC. EXEL

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications. With a rational and disciplined approach to investment, we are leveraging our internal experience and expertise and the strength of strategic partnerships, to identify and pursue opportunities across the landscape of scientific modalities, including small molecules and biotherapeutics, such as antibody-drug conjugates (ADCs).

Last close 64.53 2026-10-23
Market cap $15.99B 2026-07-03 share count
52-week range 36.00 - 65.50

Valuation FY2025 figures against the last close

P/S6.9x
P/E23.2x
P/FCF18.3x
EV/EBITDA17.7x
Dividend yield—
Diluted EPS2.78

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S.
  • Europe
  • Japan
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 U.S., FY2025: 2.1B (92.3%) 92% U.S. Europe, FY2025: 154.2M (6.6%) 7% Europe Japan, FY2025: 25.6M (1.1%) FY2024 U.S., FY2024: 1.8B (84.1%) 84% Europe, FY2024: 318.6M (14.7%) 15% Japan, FY2024: 27.1M (1.2%) FY2023 U.S., FY2023: 1.6B (89.9%) 90% Europe, FY2023: 145M (7.9%) 8% Japan, FY2023: 39.5M (2.2%)
Region FY2025FY2024FY2023
U.S. $2.14B $1.82B $1.65B
Europe $154.2M $318.6M $145.0M
Japan $25.6M $27.1M $39.5M

As the company reported it, from the “Revenues - Revenues Disaggregated by Geographic Region (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $2.32B$2.17B$1.83B$1.61B$1.43B$987.5M$967.8M$853.8M$452.5M$191.5M
Cost of revenue $83.7M$76.2M$72.5M$57.9M$52.9M$36.3M$33.1M$26.3M$15.1M$6.6M
Gross profit $2.24B$2.09B$1.76B$1.55B$1.38B$951.3M$934.7M$827.5M$437.4M$184.9M
R&D $825.0M$910.4M$1.04B$891.8M$693.7M$547.9M$337.0M$182.3M$112.2M$96.0M
SG&A $518.7M$492.1M$542.7M$459.9M$401.7M$293.4M$228.2M$206.4M$159.3M$116.1M
Total operating expenses $1.45B$1.56B$1.66B$1.41B$1.15B$877.5M$598.3M$415.0M$286.6M$219.6M
Operating income $872.2M$604.6M$170.9M$201.5M$286.7M$110.1M$369.5M$438.9M$165.9M-$28.1M
Interest expense ——————$0$0$8.7M$33.1M
Pre-tax income $941.2M$681.7M$257.6M$234.4M$294.2M$130.8M$398.1M$452.1M$158.6M-$70.2M
Income tax $158.6M$160.4M$49.8M$52.1M$63.1M$19.1M$77.1M$238.0M$4.3M$0
Net income $782.6M$521.3M$207.8M$182.3M$231.1M$111.8M$321.0M$690.1M$154.2M-$70.2M
EPS, basic 2.881.800.650.570.730.361.062.320.52-0.28
EPS, diluted 2.781.760.650.560.720.351.022.210.49-0.28
Shares, diluted (wtd. avg.) 281.9M296.1M321.5M324.6M322.4M318.0M315.0M312.8M312.0M250.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $482.5M$217.4M$263.0M$502.7M$663.9M$320.8M$268.1M$315.9M$188.3M$155.8M
Short-term investments $576.6M$893.9M$732.3M$807.3M$819.9M$887.3M$585.7M$378.6M$204.6M$268.1M
Receivables $286.9M$265.4M$237.4M$214.8M$282.6M$160.9M$119.1M$162.8M$77.3M$40.4M
Inventory $21.7M$22.4M$17.3M$33.3M$27.5M$21.0M$12.9M$9.8M$6.7M$3.3M
Total current assets $1.44B$1.47B$1.32B$1.62B$1.83B$1.45B$1.01B$897.0M$484.9M$469.0M
Property, plant and equipment $99.0M$119.4M$128.7M$110.6M$104.0M$67.4M$48.9M$50.9M$25.7M$2.1M
Goodwill $63.7M$63.7M$63.7M$63.7M$63.7M$63.7M$63.7M$63.7M$63.7M$63.7M
Total assets $2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89B$1.42B$655.3M$595.7M
Accounts payable $29.6M$38.2M$33.8M$32.7M$24.3M$23.6M$11.6M$10.9M$9.6M$6.6M
Short-term debt —————————$189.1M
Total current liabilities $405.6M$403.8M$394.3M$324.4M$337.6M$204.7M$142.7M$105.5M$115.2M$268.8M
Long-term debt ————————$0$189.1M
Total liabilities $683.1M$703.5M$678.4M$583.1M$405.6M$258.2M$199.7M$134.8M$370.3M$506.4M
Retained earnings -$76.8M-$98.6M-$173.4M-$34.2M-$216.5M-$447.6M-$559.4M-$880.4M-$1.83B-$1.98B
Total equity $2.16B$2.24B$2.26B$2.49B$2.21B$1.88B$1.69B$1.29B$285.0M$89.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $884.3M$700.0M$333.3M$362.6M$400.8M$209.0M$527.0M$415.7M$165.6M$210.4M
Depreciation and amortisation $29.1M$28.8M$25.7M$20.9M$13.6M$9.1M$8.3M$4.9M$1.2M$1.0M
Stock-based compensation $113.0M$93.8M$106.3M$107.6M$119.8M$105.1M$56.6M$40.6M$23.9M$22.9M
Capital expenditure $8.4M$28.4M$40.5M$27.7M$54.2M$30.3M$12.8M$33.3M$21.1M$1.7M
Investing cash flow $350.4M-$116.8M-$27.0M-$524.4M-$42.9M-$131.2M-$587.2M-$297.9M$36.8M-$214.5M
Financing cash flow -$969.6M-$628.8M-$546.1M$586.0K-$14.8M-$25.1M$12.6M$9.7M-$169.9M$15.7M
Buybacks $947.5M$652.0M$550.4M$0$0—————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000939767-26-000046.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2016: 191.5M Gross profit, FY2016: 184.9M Net income, FY2016: -70.2M Revenue, FY2017: 452.5M Gross profit, FY2017: 437.4M Net income, FY2017: 154.2M Revenue, FY2018: 853.8M Gross profit, FY2018: 827.5M Net income, FY2018: 690.1M Revenue, FY2019: 967.8M Gross profit, FY2019: 934.7M Net income, FY2019: 321M Revenue, FY2020: 987.5M Gross profit, FY2020: 951.3M Net income, FY2020: 111.8M Revenue, FY2021: 1.4B Gross profit, FY2021: 1.4B Net income, FY2021: 231.1M Revenue, FY2022: 1.6B Gross profit, FY2022: 1.6B Net income, FY2022: 182.3M Revenue, FY2023: 1.8B Gross profit, FY2023: 1.8B Net income, FY2023: 207.8M Revenue, FY2024: 2.2B Gross profit, FY2024: 2.1B Net income, FY2024: 521.3M Revenue, FY2025: 2.3B Gross profit, FY2025: 2.2B Net income, FY2025: 782.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $191.5M $452.5M $853.8M $967.8M $987.5M $1.43B $1.61B $1.83B $2.17B $2.32B
Gross profit $184.9M $437.4M $827.5M $934.7M $951.3M $1.38B $1.55B $1.76B $2.09B $2.24B
Net income -$70.2M $154.2M $690.1M $321.0M $111.8M $231.1M $182.3M $207.8M $521.3M $782.6M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%
TECH BIO-TECHNE Corp $11.38B 62.5x -0.4%